BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• 

  Career Advice

  Career Coach: Boost Your Career With This End-of-Year Action Plan

  Learn how to leverage your end-of-year downtime to document achievements, update your professional presence and prepare for a successful 2025.

  December 12, 2024

   · 

  5 min read

   · 

  Carina Clingman
• 

  Government

  Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner

  A week after dining with Trump and his team at Mar-a-Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration on key issues affecting the pharma industry.

  December 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Legal

  Former CytoDyn Official Found Guilty of Securities Fraud

  Former president and CEO of CytoDyn Nader Pourhassan along with Kazem Kazempour, former CEO of the CRO running CytoDyn’s trials, are awaiting sentencing but could face up to 20 years in prison for each count of securities and wire fraud and insider trading.

  December 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Career Advice

  The Right Fit: What BMS, Intellia Look for in Cell and Gene Therapy Talent

  When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent acquisition executives from Bristol Myers Squibb and Intellia Therapeutics offer an inside look at what they want in an employee.

  December 12, 2024

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Prostate cancer

  Candel Stock Skyrockets on Promising Phase III Prostate Cancer Data

  Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a basis for a regulatory application.

  December 12, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Cardiovascular disease

  Keros Suspends Two Arms of Hypertension Study After Reports of Pericardial Effusion

  Keros’ stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure until the safety concerns for cibotercept are resolved.

  December 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Phase III

  Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication

  Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of breast cancer.

  December 12, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Regulatory

  Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe

  The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of death by 20%.

  December 12, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• Press Releases

  SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

  December 12, 2024

   · 

  9 min read
• Press Releases

  IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

  December 12, 2024

   · 

  4 min read